Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2018 | Advances in targeted therapies for ALL

David Marks • 14 Jun 2018
EHA 2018
Acute Lymphoblastic Leukemia Leukemia Antibodies Blinatumomab CAR-T Inotuzumab ozogamicin
TOWER

Speaking from the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden, David Marks, MBBS, PhD, FRACP, FRCPath, of University Hospitals Bristol NHS Foundation Trust, Bristol, UK, discusses the newest and most promising targeted ALL therapies. Prof. Marks discusses blinatumomab, which has shown impressive results in establishing MRD negativtiy, and CAR T-cells, which may offer the hope of long-term survival to patients who were previously considered to be incurable.

More from David Marks

1:56
The feasibility of chemotherapy-free regimens without allogeneic transplantation in MRD- Ph+ALL
David Marks • 24 Apr 2023
3:36
UKALL14: rituximab dose & reduced intensity transplant in B-ALL & nelarabine consolidation in T-ALL
David Marks • 24 Apr 2023
1:37
The importance of MRD assessment before alloSCT in ALL
David Marks • 24 Apr 2023
3:24
Improving risk stratification in ALL with risk scores & genomic studies to personalize therapy
David Marks • 24 May 2023

Related Videos

1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals